Form 4: Acadia Pharmaceuticals Executive Brendan Teehan Reports Stock Transactions

EVP, COO, and Head of Commercial Brendan Teehan reports acquisition and disposal of Acadia Pharmaceuticals stock related to vesting of performance stock units and tax obligations.

Summary

• Brendan Teehan, EVP, COO, and Head of Commercial at Acadia Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On August 16, 2024, Teehan acquired 5,024 shares of common stock upon vesting of performance stock units granted on April 5, 2022, at an incremental 25% of target.
• An additional 13,629 shares were acquired on the same date upon vesting of performance stock units granted on May 1, 2023, at 50% of target.
• Teehan also acquired 925 shares through the Employee Stock Purchase Plan on May 15, 2024.
• On August 19, 2024, Teehan sold 9,534 shares at a weighted average price of $15.28 to cover withholding taxes related to the vesting of performance stock units.
• Following these transactions, Teehan beneficially owns 52,177 shares of Acadia Pharmaceuticals stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing primarily reports routine stock transactions related to compensation and tax obligations. There is no indication of significant positive or negative sentiment.

Positives

• The vesting of performance stock units indicates that performance targets are being met, which could be viewed positively.

Negatives

• The sale of shares to cover tax obligations could be interpreted as a need for liquidity, although it is a common practice.

Risks

• The Form 4 filing itself doesn't inherently indicate risks, but the stock transactions are subject to market fluctuations and company performance.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives.
• The transactions reported are typical for executives receiving stock-based compensation and managing their tax obligations.
• Similar filings can be observed for executives at comparable pharmaceutical companies such as Biogen, Amgen, and Vertex Pharmaceuticals.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the overall impact is likely minimal.

Key Dates